午夜福利二三区免费看,国产一区二区在线影院,国产成人凹凸视频在线

Elsulfavirine

NMR下載 COA and HPLC MSDS下載
names：
Elsulfavirine
CAS號：
868046-19-9
MDL Number： No data available
MF(分子式)： C24H17BrCl2FN3O5S MW(分子量)： 629.28
EINECS:No data available Reaxys Number:No data available
Pubchem ID:11527519 Brand:BIOFOUNT

(868046-19-9)Elsulfavirine是HIV-1感染的逆轉錄酶的抑制劑,也是一種有效的抗 HIV 的新型藥物.

貨品編碼	規格	純度	價格 (￥)	現價(￥)	特價(￥)	庫存描述	數量	總計 (￥)
YZM000674-250mg	250mg	>97%	￥ 0.00	￥ 0.00		Backorder	- +	￥ 0.00
YZM000674-100mg	100mg	>97%	￥ 0.00	￥ 0.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯系人：

*電話：

*驗證碼：

詢價

中文別名	Elsulfavirine(868046-19-9);
英文別名	Elsulfavirine(868046-19-9);Elpida;2-[4-bromo-3-(3-chloro-5-cyano-phenoxy)-2-fluoro-phenyl]-N-(2-chloro-4-propionylsulfamoyl-phenyl)-acetamide;
CAS號	868046-19-9
Inchi	InChI = 1S / C24H17BrCl2FN3O5S / c1-2-21（32）31-37（34,35）17-4-6-20（19（27）11-17）30-22（33）9-14-3- 5-18（25）24（23（14）28）36-16-8-13（12-29）7-15（26）10-16 / h3-8,10-11H，2,9H2,1H3，（H，30,33）（H，31,32）
InchiKey	ULTDEARCBRNRGR-UHFFFAOYSA-N
分子式 Formula	C24H17BrCl2FN3O5S
分子量 Molecular Weight	629.28
溶解度Solubility
性狀	Solid
儲藏條件 Storage conditions	請根據產品建議的存儲條件進行存儲,Please store the product under the recommended condition sin the description.

Elsulfavirine(868046-19-9)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業生物廢氣物處理公司處理，以免造成環境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tags；Elsulfavirine試劑,Elsulfavirine雜質,Elsulfavirine中間體,Elsulfavirine密度,Elsulfavirine溶解度,Elsulfavirine旋光度,Elsulfavirine合成,Elsulfavirine閃點,Elsulfavirine熔點,Elsulfavirine結構式,Elsulfavirine購買,

產品說明	(868046-19-9)Elsulfavirine 是HIV-1感染的逆轉錄酶的抑制劑,也是一種有效的抗 HIV 的新型藥物.
Introduction	Elsulfavirine(868046-19-9) is a reverse transcriptase inhibitors forHIVinfection and is a new antiIV drug.
Application1
Application2
Application3

Elsulfavirine(868046-19-9)藥理學：

(868046-19-9)Elsulfavirine 是HIV-1感染的逆轉錄酶的抑制劑,也是一種有效的抗 HIV 的新型藥物.

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續沖洗+P337如果眼睛刺激持續+P2393獲得醫療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Elsulfavirine: First Global Approval PMID 28940154; Drugs 2017 Oct; 77(16):1811-1816 (Review Article) Name matches: nucleoside elsulfavirine

Emerging reverse transcriptase inhibitors for HIV-1 infection PMID 29737220; Expert opinion on emerging drugs 2018 06; 23(2):149-157 (Review Article) Name matches: nucleoside elsulfavirine

Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment PMID 31556749; Expert opinion on drug metabolism & toxicology 2019 Oct; 15(10):813-829 (Review Article

Emerging reverse transcriptase inhibitors for HIV-1 infection PMID 29737220; Expert opinion on emerging drugs 2018 06; 23(2):149-157 (Review Article) Name matches: hiv-1 infection elsulfavirine

Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors PMID 30417402; Medicinal research reviews 2019 07; 39(4):1235-1273 (Re

Elsulfavirine(868046-19-9)參考文獻：

1、Novel Antiretroviral Agents Mary C. Cambou & Raphael J. Landovitz

Abstract：Purpose of Review Combination antiretroviral therapy (cART) has had dramatic effects on morbidity and mortality for persons living with HIV (PLWH). Despite significant progress in treatment efficacy, tolerability, and reducing pill burden, new agents are needed to address issues of resistance, drug-drug interactions, end organ disease, and adherence. This review covers novel ART agents recently approved or in development. Recent Findings Capsid inhibitors (CAI) demonstrate high potency and potential for extended-duration dosing in pre-clinical trials. While previous maturation inhibitors (MI) were hampered by issues of drug resistance, a recent phase IIa trial for a second-generation MI demonstrated promising antiviral activity. A phase I trial to evaluate a transdermal implant of islatravir, a nucleoside reverse transcriptase translocation inhibitor (NRTTI), maintained concentrations above the target pharmacokinetic threshold at 12 weeks. The attachment inhibitor fostemsavir is available in the USA for compassionate use in multi-drug-resistant (MDR) HIV. Summary New antiretroviral agents show promise for both extended-duration dosing and MDR HIV.

2、Focus on recently developed assays for detection of resistance/sensitivity to reverse transcriptase inhibitors
Francesca Marino-Merlo, Beatrice Macchi, Daniele Armenia, Maria Concetta Bellocchi, Francesca Ceccherini-Silberstein, Antonio Mastino & Sandro Grelli???????

Abstract：The biology of HIV is rather complex due to high rate of replication, frequent recombination, and introduction of mutations. This gives rise to a number of distinct variants referred as quasispecies. In addition, the latency within reservoir allows the periodic reactivation of virus replication. The rapid replication of HIV allows immune response escape and establishment of resistance to therapy that can be acquired through drug selection and/or transmitted among individuals. This prompted, over the years, the development of a range of assays aimed to determine drug resistance and sensitivity, to be used both in clinical practice and in antiviral research. Reverse transcriptase (RT) inhibitors have an eminent place among the anti-HIV drugs, being constantly present from the beginning until today in the most commonly used antiviral regimens. This mini-review seeks to provide an up-to-date overview of recent efforts in developing even more reliable and simple methods, of both genotypic and phenotypic types, for specifically detecting drug resistance and sensitivity to RT inhibitors.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開